戈利木单抗生物类似药（Alvotech）(Golimumab biosimilar (Alvotech)) - 药物靶点：TNF-α_在研适应症：强直性脊柱炎，非放射性轴性脊柱关节炎，多关节型幼年特发性关节炎_专利_临床

概要

基本信息

药物类型

生物类似药、单克隆抗体

别名

Golimumab Biosimilar (Alvotech hf)、戈利木单抗生物类似药（Alvotech hf）、AVT-05

+ [3]

靶点

TNF-α

作用方式

抑制剂

作用机制

TNF-α抑制剂(肿瘤坏死因子α抑制剂)

治疗领域

免疫系统疾病感染消化系统疾病+ [2]

在研适应症

强直性脊柱炎非放射性轴性脊柱关节炎多关节型幼年特发性关节炎+ [8]

非在研适应症-

原研机构

Alvotech hf

在研机构

Advanz Pharma Ltd.

Advanz Pharma Corp. Ltd.Alvotech

+ [4]

非在研机构-

权益机构

Fuji Pharma Co., Ltd.

Alvotech hf

STADA Arzneimittel AG

+ [5]

最高研发阶段批准上市

首次获批日期

日本 (2025-09-19),

类风湿关节炎

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

Sequence Code 10217CDR2-L

当前序列信息引自: *****

Sequence Code 34550CDR3-L

当前序列信息引自: *****

Sequence Code 208354L

当前序列信息引自: *****

Sequence Code 1694337H

当前序列信息引自: *****

Sequence Code 13027041CDR2-H

当前序列信息引自: *****

Sequence Code 535237464CDR3-H

当前序列信息引自: *****

Sequence Code 559603504CDR1-L

当前序列信息引自: *****

Sequence Code 1167865419CDR1-H

当前序列信息引自: *****

关联

2

项与戈利木单抗生物类似药（Alvotech）相关的临床试验

NCT05842213

/ Completed临床3期

Randomized, Double-blind, 2-arm Multicenter Study to Investigate the Efficacy, Safety and Immunogenicity Between Subcutaneous AVT05 and EU-approved Simponi® in Subjects with Moderate to Severe Rheumatoid Arthritis

This is a study to compare the efficacy, safety and immunogenicity of AVT05 versus EU-Simponi® in combination with methotrexate (MTX) in subjects with moderate to severe rheumatoid arthritis (RA).
The study will consist of up to 4-week Screening Period, a 48-week Treatment Period, and a 4-week Safety Follow-up Period.

开始日期2023-03-30

申办/合作机构

Alvotech Swiss AG

NCT05632211

/ Completed临床1期

A First-in-human, Randomized, Parallel Group, Double-blind, 3-arm Study to Investigate the Comparative PK, Safety, and Tolerability Between Subcutaneous AVT05, US-licensed Simponi®, and EU-approved Simponi® in Healthy Adult Participants

Rationale:
Alvotech is developing AVT05 globally as a proposed biosimilar to the reference product Simponi (golimumab) for subcutaneous (SC) use. This is a first-in-human (FIH) clinical study with AVT05. The study aims to demonstrate pharmacokinetic (PK) similarity of the proposed biosimilar test product AVT05 and the reference products EU approved Simponi and US-licensed Simponi, in addition to evaluating the safety and tolerability of AVT05, when administered as a single 50 mg/0.5 mL SC dose.

开始日期2022-12-16

申办/合作机构

Alvotech Swiss AG

[+1]

100 项与戈利木单抗生物类似药（Alvotech）相关的临床结果

登录后查看更多信息

100 项与戈利木单抗生物类似药（Alvotech）相关的转化医学

登录后查看更多信息

100 项与戈利木单抗生物类似药（Alvotech）相关的专利（医药）

登录后查看更多信息

2

项与戈利木单抗生物类似药（Alvotech）相关的文献（医药）

2026-01-01·BIODRUGS

Pharmacokinetic Similarity of Biosimiliar AVT05 Versus Reference Product Golimumab in Healthy Adults: A Double-Blind, Three-Arm, Parallel-Group Study

Article

作者: Wynne, Chris ; Lorch, Ulrike ; Rai, Masna ; Ashdown, Thomas ; Berti, Fausto ; Krantz, Edrich ; Leutz, Steffen ; Ruffieux, Ruth ; Vashishta, Laxmikant ; Luque, Monica ; Katial, Rohit ; Petrovic, Katarina ; Sattar, Abid

BACKGROUND:

AVT05, a recombinant, human, immunoglobulin G1қ monoclonal antibody, is a biosimilar to Simponi^®.

OBJECTIVES:

The purpose of this study was to investigate the pharmacokinetic (PK) similarity, safety, tolerability, and immunogenicity between AVT05 and US-licensed and European Union (EU)-approved reference product (RP) golimumab (US-RP and EU-RP, respectively) in healthy adult participants.

METHODS:

Three hundred and thirty-six healthy male and female participants aged 18-55 years were randomized in a 1:1:1 ratio to AVT05, US-RP, or EU-RP. Participants received a single 50 mg/0.5 mL subcutaneous injection on Day 1 and were followed until Day 75. The primary PK endpoints were maximum serum concentration (C_max) and area under the serum concentration-time curve from time zero to infinity (AUC_0-inf). Pharmacokinetic similarity was demonstrated if the 90% confidence intervals for the geometric mean ratio for both AUC_0-inf and C_max were entirely contained within the prespecified margins of 80.00% and 125.00% for all six pairwise treatment comparisons. Secondary endpoints were additional PK parameters (area under the concentration-time curve from time zero to the last quantifiable concentration, time to C_max, terminal elimination rate constant, terminal elimination half-life, apparent volume of distribution, and apparent clearance), safety, tolerability, and immunogenicity.

RESULTS:

Demographic and baseline characteristics were balanced between the treatment groups. The 90% confidence intervals for the geometric means ratio for the protein-adjusted primary PK parameters were entirely contained within the prespecified margins of 80.00% and 125.00% (C_max [AVT05/US-RP 89.45, 106.75; AVT05/EU-RP 92.33, 110.15; EU-RP/US-RP 88.64, 105.92]; AUC_0-inf [AVT05/US-RP 94.35, 108.40; AVT05/EU-RP 98.46, 113.13; EU-RP/US-RP 89.36, 102.76]), supporting the demonstration of PK similarity. The secondary PK parameters were also comparable between the treatment arms. The mean serum golimumab concentrations through Day 75 post-dose were similar between treatment arms. Overall, 66.1% of participants experienced at least one treatment-emergent adverse event (TEAE) during the study period. The frequency of TEAEs was comparable across the treatment arms. The majority of TEAEs were mild to moderate in severity. There were two serious TEAEs reported (one [0.9%] each in AVT05 and EU-RP arms), neither of which was considered treatment related. Local administration site reactions were mild in severity and observed in 6.1%, 10.8%, and 5.5% of participants in the AVT05, EU-RP, and US-RP arms, respectively. Overall, 87 (75.7%), 92 (82.9%), and 89 (80.9%) participants in the AVT05, EU-RP, and US-RP arms, respectively, were anti-drug antibody positive; among those 66 (57.4%), 68 (61.3%), and 61 (55.5%) participants, respectively, were neutralizing antibody positive at least once during the study. The primary PK parameters (AUC_0-inf and C_max) were slightly lower in antidrug antibody-positive participants compared with antidrug antibody-negative participants.

CONCLUSIONS:

Following single-dose administration, the study supported a demonstration of PK similarity between AVT05 and EU-RP and US-RP in healthy participants. Safety, tolerability, and immunogenicity profiles were comparable between the treatment arms.

CLINICAL TRIAL REGISTRATION:

The trial is registered at ClinicalTrials.gov (CT.gov identifier: NCT05632211).

2026-01-01·BIODRUGS

Efficacy and Safety of Biosimilar AVT05 Versus Reference Product Golimumab in Combination with Methotrexate in Moderate-to-Severe Rheumatoid Arthritis: 52-Week Results of a Randomized, Parallel-Group, Double-Blind Study

Article

作者: Sattar, Abid ; Rai, Masna ; Zhelyazkova, Kristina ; Petrovic, Katarina ; Berti, Fausto ; Leutz, Steffen ; Bucknall, Richard ; Vashishta, Laxmikant ; Luque, Monica

BACKGROUND:

Golimumab is a safe and effective treatment for patients with rheumatoid arthritis. Biosimilars to the reference product (RP; Simponi^®) may make treatment more accessible.

OBJECTIVES:

The aim of this study was to assess the efficacy of AVT05, a golimumab biosimilar, and RP, each used in combination with methotrexate, in participants with moderate-to-severe rheumatoid arthritis.

METHODS:

This was a 52-week, randomized, double-blind, two-arm, parallel-group, active-controlled study. Participants were randomized 1:1 to receive AVT05 (n = 251) or RP (n = 251), 50 mg subcutaneously once every 4 weeks to Week 12 inclusive. Randomization was stratified by the baseline Disease Activity Score-28 for Rheumatoid Arthritis using C-Reactive Protein (DAS28-CRP) [≤ 5.1 and > 5.1]. The primary endpoint was the change from baseline in DAS28-CRP at Week 16. At Week 16, responder participants (DAS28-CRP decreased by > 0.6 from baseline and disease activity DAS28-CRP ≤ 5.1) initially enrolled in the AVT05 arm continued to receive AVT05 every 4 weeks. Responder participants initially randomized to RP were re-randomized 1:1 to either continue receiving RP or switch to AVT05. Non-responders were discontinued from the study drug. Change from baseline in DAS28-CRP response criteria at weeks 4, 8, 12, 24, 32, 40, 48, and 52 and percentage of subjects achieving American College of Rheumatology 20/50/70 at weeks 4, 8, 12, 16, 24, 32, 40, 48, and 52 were assessed as secondary endpoints. Safety and immunogenicity endpoints were also assessed.

RESULTS:

At Week 16, the least squares mean (standard error) change from baseline in DAS28-CRP in AVT05 and RP was - 2.89 (0.058) and - 2.98 (0.058), respectively. The two-sided 95% confidence interval of the least squares mean difference (0.09; standard error 0.082) was entirely contained within the prespecified equivalence margin of - 0.6, 0.6 (- 0.07, 0.25), supporting a demonstration of comparative efficacy. Two sensitivity analyses (one [S1] without exclusion of any data because of intercurrent events, and one [S2] excluding data following intercurrent events or relevant protocol deviations) supported the robustness of the primary endpoint estimates (S1 95% confidence interval - 0.07, 0.25; S2 95% confidence interval - 0.07, 0.25). There were no notable differences in subgroup analyses. Secondary efficacy analyses were consistent with the primary endpoint, including in participants who switched treatments. Overall safety profiles showed no clinically meaningful differences between treatments, including in participants who switched treatments. Immunogenicity profiles were comparable between treatment arms at all timepoints, including in participants who switched treatments.

CONCLUSIONS:

Analysis of the change in DAS28-CRP from baseline to Week 16 supported the assessment of comparative efficacy between AVT05 and RP golimumab. Secondary efficacy endpoints were consistent with this, including in participants who switched. AVT05 had a safety and immunogenicity profile similar to that observed for RP at all timepoints, including in participants who switched treatments.

CLINICAL TRIAL REGISTRATION:

The trial is registered at ClinicalTrials.gov (ClinicalTrials.gov identifier: NCT05842213) and the EU Clinical Trials Register (EudraCT Number: 2022-001825-63).

56

项与戈利木单抗生物类似药（Alvotech）相关的新闻（医药）

2026-03-30

·investors.alvotech.com

Alvotech files Annual Report with the SEC

REYKJAVIK, ICELAND (March 30, 2026) — Alvotech (NASDAQ: ALVO) (the “Company”) has filed its Annual Report 2025 on Form 20-F for the financial year 2025 with the U.S. Securities and Exchange Commission (SEC), incorporating by reference parts of the Alvotech Annual Report 2025. The report is available on the SEC’s website, www.sec.gov, as well as in the investor relations section of Alvotech’s website at https://investors.alvotech.com/financials. For further information, contact: Media Benedikt Stefansson Sarah MacLeod alvotech.media@alvotech.com Investors Dr. Balaji V Prasad (US) Patrik Ling (SE) Benedikt Stefansson (IS) alvotech.ir@alvotech.com About Alvotech Alvotech is a biotechnology company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in biosimilars by delivering high-quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Five biosimilars are already approved and marketed in multiple global markets, including biosimilars to Humira® (adalimumab), Stelara® (ustekinumab), Simponi® (golimumab), Eylea® (aflibercept) and Prolia®/Xgeva® (denosumab). The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. For more information, please visit https://www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release. For more information, please visit our investor portal, and our website or follow us on social media on LinkedIn, Facebook, Instagram and YouTube.

生物类似药

2026-03-30

·investors.alvotech.com

Alvotech Publishes 2025 Annual Report

REYKJAVIK, ICELAND (March 30, 2026) — Alvotech (NASDAQ: ALVO) (the “Company”) has published its Annual Report for 2025. The report is available in the investor relations section of Alvotech’s website at: https://investors.alvotech.com/financials and is attached to this announcement in PDF and iXBRL formats. For further information, contact: Media Benedikt Stefansson Sarah MacLeod alvotech.media@alvotech.com Investors Dr. Balaji V Prasad (US) Patrik Ling (SE) Benedikt Stefansson (IS) alvotech.ir@alvotech.com About Alvotech Alvotech is a biotechnology company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in biosimilars by delivering high-quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Five biosimilars are already approved and marketed in multiple global markets, including biosimilars to Humira® (adalimumab), Stelara® (ustekinumab), Simponi® (golimumab), Eylea® (aflibercept) and Prolia®/Xgeva® (denosumab). The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. For more information, please visit https://www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release. For more information, please visit our investor portal, and our website or follow us on social media on LinkedIn, Facebook, Instagram and YouTube. Attachments Alvotech Consolidated Financial Statements FY 2025 222100DCZBOWV5DZ8372-2025-12-31-1-en

生物类似药

2026-03-21

·雪球

Alvotech2025财年四季报业绩会议总结

一、开场介绍会议时间：2025年第四季度主持人说明：介绍会议目的为公布2025年全年及第四季度财务业绩，相关材料已发布于投资者门户网站；提示可能包含前瞻性陈述，存在风险和不确定性。管理层发言摘要：RobertWessman（创始人、董事长兼执行董事长）：2025年是关键一年，巩固全球领先生物类似药开发商地位，解决FDA对雷克雅未克生产设施的监管意见，推进30种生物类似药管线，财务表现增长（总收入增长20%，调整后EBITDA增长27%），LisaGraver接任首席执行官，公司进入运营执行和商业规模新阶段。二、财务业绩分析核心财务数据全年收入：5.93亿美元（同比增长21%），产品收入与许可收入各占50%；全年调整后EBITDA：1.37亿美元（同比增长27%），利润率23%；第四季度收入：1.73亿美元（同比增长13%），其中许可收入占75%；第四季度调整后EBITDA：6900万美元，利润率40%；产品利润率：第四季度为-37%，全年运营现金流首次为正（700万美元）；年终现金余额：1.72亿美元，得益于第四季度融资（1.08亿美元可转换债券+1亿美元高级定期贷款）。关键驱动因素收入增长主要由许可收入推动，得益于开发进展及美国以外新launch相关的性能里程碑；产品销售疲软受订单时间安排和为支持即将到来的launch进行的计划设施升级影响；毛利率受许可收入占比高推动（全年61%，第四季度66%）。三、业务运营情况分业务线表现现有产品：修美乐生物类似药（AVT02）在美国市场份额约9%，为细分市场第二大且增长最快的生物类似药之一；喜达诺生物类似药（AVT04）在美国生物类似药市场占40%份额，欧洲Uzpruvo在生物类似药细分市场占超20%份额；新获批产品：AVT03（地诺单抗）、AVT05（类克）、AVT06（阿柏西普）在欧洲、英国、日本等市场获批并launch，其中AVT05在欧洲、日本为首个获批的类克生物类似药，AVT06在日本为首个获批的阿柏西普生物类似药。市场拓展商业合作伙伴：与梯瓦（美国launchSelarsdi）、AdvanzPharma（Cimzia项目）、Dr.Reddy's（Keytruda项目）、山德士（扩大市场覆盖）等合作，全球商业网络持续扩展；地域覆盖：在欧洲、英国、日本、加拿大等市场推进产品批准和launch，美国市场等待FDA重新提交申请后的批准。研发投入与成果管线进展：30种生物类似药在研，覆盖全球销售额超1.85亿美元的市场；Entyvio生物类似药关键药代动力学研究结果积极，预计2026年晚些时候提交监管申请；Keytruda生物类似药预计2028年提交上市申请；监管策略：预见FDA生物类似药开发draft指南变化，调整开发战略，减少对大型疗效试验的依赖，降低成本和时间。运营效率生产设施：解决FDA对雷克雅未克工厂的监管意见，实施全面质量改进计划，预计2026年第二季度重新提交申请；推进关键产品双重来源生产，评估美国CMO合作，减少单一基地依赖；产能扩张：收购Ivers-Lee增强组装包装能力，收购Xbrane研发团队增强工艺开发，雷克雅未克工厂增加新原料药和制剂生产套件。四、未来展望及规划短期目标（2026年）财务预期：收入6.5亿-7亿美元（两位数增长），调整后EBITDA1.8亿-2.2亿美元（下限假设无美国launch收入）；战略重点：推进美国FDA申请重新提交（第二季度），实现年底前获批；扩大已批准产品在欧洲、日本等市场的商业launch；完成关键产品双重来源生产合作。中长期战略行业趋势：生物类似药市场长期驱动因素强劲，全球药品销售额40%来自生物制剂，未来十年超100种生物制剂失去专利保护；公司定位：利用FDA新指南降低研发成本，保持行业领先的管线开发速度（每两个月启动一个新项目）；投资方向：扩展制造足迹（美国为重点），加强供应链弹性，深化全球商业合作伙伴关系。五、问答环节要点FDA批准进展问：FDA补救计划完成情况及重新提交后获批信心？答：已完成补救措施，正收集改进有效性信息，预计2026年第二季度重新提交；FDA可能进行额外检查，但将提交全面回应以减少检查需求。财务指导细节问：2026年指导范围（6.5亿-7亿美元）是否包含美国新launch收入？答：下限未包含美国launch收入，上限包含许可收入和产品销售增长；指导基于已获批产品在欧美日等市场的launch势头。制造扩张与成本问：双重来源生产的时间安排、成本及对研发费用的影响？答：上半年确定合作方，成本在预期研发支出范围内，不额外增加资本支出；目标是增强供应弹性和商业合作伙伴价值。竞争风险应对问：如何减轻生物类似药市场竞争风险？答：通过先发优势（开发速度、早期监管策略）、知识产权布局、与强商业伙伴合作（如梯瓦、STADA）快速渗透市场，选择高壁垒项目。产品销售趋势问：修美乐生物类似药（AVT02）销售疲软是否为信号？答：季度波动属B2B业务正常现象，2025年美国市场份额达9%，预计2026年随品牌药侵蚀（生物类似药占比55%）持续增长；产品毛利率2026年将回升。六、总结发言管理层表示：Alvotech已建立整合的生物类似药平台，2025年扩展平台同时加强运营基础；未来优先事项：推进产品在全球市场的批准和商业化，关注运营卓越、效率与合规，扩展制造足迹和管线，利用行业趋势抓住生物类似药机遇；强调团队将继续执行战略，打造全球领先的生物类似药公司。查看业绩会议全文

生物类似药财报

100 项与戈利木单抗生物类似药（Alvotech）相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	L04AB06	-

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
强直性脊柱炎	欧盟	Advanz Pharma Ltd.	2025-11-17
强直性脊柱炎	冰岛	Advanz Pharma Ltd.	2025-11-17
强直性脊柱炎	列支敦士登	Advanz Pharma Ltd.	2025-11-17
强直性脊柱炎	挪威	Advanz Pharma Ltd.	2025-11-17
非放射性轴性脊柱关节炎	欧盟	Advanz Pharma Ltd.	2025-11-17
非放射性轴性脊柱关节炎	冰岛	Advanz Pharma Ltd.	2025-11-17
非放射性轴性脊柱关节炎	列支敦士登	Advanz Pharma Ltd.	2025-11-17
非放射性轴性脊柱关节炎	挪威	Advanz Pharma Ltd.	2025-11-17
多关节型幼年特发性关节炎	欧盟	Advanz Pharma Ltd.	2025-11-17
多关节型幼年特发性关节炎	冰岛	Advanz Pharma Ltd.	2025-11-17
多关节型幼年特发性关节炎	列支敦士登	Advanz Pharma Ltd.	2025-11-17
多关节型幼年特发性关节炎	挪威	Advanz Pharma Ltd.	2025-11-17
活动性中度溃疡性结肠炎	欧盟	Advanz Pharma Ltd.	2025-11-17
活动性中度溃疡性结肠炎	冰岛	Advanz Pharma Ltd.	2025-11-17
活动性中度溃疡性结肠炎	列支敦士登	Advanz Pharma Ltd.	2025-11-17
活动性中度溃疡性结肠炎	挪威	Advanz Pharma Ltd.	2025-11-17
活动性重度溃疡性结肠炎	欧盟	Advanz Pharma Ltd.	2025-11-17
活动性重度溃疡性结肠炎	冰岛	Advanz Pharma Ltd.	2025-11-17
活动性重度溃疡性结肠炎	列支敦士登	Advanz Pharma Ltd.	2025-11-17
活动性重度溃疡性结肠炎	挪威	Advanz Pharma Ltd.	2025-11-17

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
免疫系统疾病	临床前	冰岛	Alvotech hf	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05632211 (Pubmed \| BioDrugs)	临床3期	-	336	AVT05	選網選鬱顧遞積窪夢鏇(選憲齋網簾醖顧願鬱鑰) = The 90% confidence intervals for the geometric means ratio for the protein-adjusted primary PK parameters were entirely contained within the prespecified margins of 80.00% and 125.00% (AUC0-inf [AVT05/US-RP 94.35, 108.40; AVT05/EU-RP 98.46, 113.13; EU-RP/US-RP 89.36, 102.76]) 醖鏇鑰獵鏇觸夢襯鏇蓋 (築醖鑰鑰鹽願襯構範窪 ) 更多	积极	2025-11-10
				US-licensed reference product (Simponi™)
NCT05632211 (CTgov)	临床1期	-	336	AVT05 (AVT05 50mg s.c.)	選醖憲簾齋齋網願艱蓋(繭願顧網鏇繭衊糧獵簾) = 獵獵廠鬱簾齋網獵齋鑰淵鏇觸鹽網蓋餘構網鑰 (獵鹽壓積壓糧糧範蓋願, 52) 更多	-	2025-05-28
				Simponi (EU Simponi 50mg s.c.)	選醖憲簾齋齋網願艱蓋(繭願顧網鏇繭衊糧獵簾) = 醖廠廠艱製獵鏇簾廠網淵鏇觸鹽網蓋餘構網鑰 (獵鹽壓積壓糧糧範蓋願, 50) 更多
NCT05842213 (ACR2024)	临床3期	类风湿关节炎	502	AVT05	鹹衊鬱廠鑰網淵獵遞廠(衊鹹鏇醖憲艱衊鏇鏇鏇) = 觸鹽觸膚壓遞淵鹽範積鏇衊獵鹽顧簾齋繭襯餘 (艱願淵糧獵鹹窪廠簾醖 ) 更多	积极	2024-11-10
				Reference Golimumab	鹹衊鬱廠鑰網淵獵遞廠(衊鹹鏇醖憲艱衊鏇鏇鏇) = 獵遞繭獵積觸廠築廠遞鏇衊獵鹽顧簾齋繭襯餘 (艱願淵糧獵鹹窪廠簾醖 ) 更多
NCT05632211 (Biospace) 人工标引	N/A	类风湿关节炎	-	AVT05	憲鏇糧廠鹹齋網襯鏇製(蓋夢蓋範繭蓋齋網窪鏇) = met its primary endpoints 鏇鹽廠膚繭鏇鹹構願鏇 (夢壓繭襯構觸網淵膚獵 ) 更多	积极	2023-11-29
				Simponi